Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 288 for “"Temozolomide"”.

  1. Circadian Regulation of Temozolomide Sensitivity in Glioblastoma

    … by testing the efficacy of the DNA alkylator Temozolomide (TMZ) on GBM in vitro and in vivo as a function of time of day. We found cell-intrinsic, daily rhythms in susceptibility of GBM tumor cells (mouse astrocytes deficient in NF1 and p53 signaling) to TMZ in vitro. The greatest TMZ-induced …

    wustl Repository record for Circadian Regulation of Temozolomide Sensitivity in Glioblastoma (opens in a new tab)

  2. Investigating acquired temozolomide resistance in adult glioblastoma

    … management includes surgery, radiotherapy and temozolomide (TMZ), which causes three types of DNA methylation: O6-methylguanine (O<sup>6</sup>-meG), N7-methylguanine and N3-methyladenine. N-methylated lesions are mostly recognised and repaired by base excision repair (BER), while the most toxic …

    oxford Repository record for Investigating acquired temozolomide resistance in adult glioblastoma (opens in a new tab)

  3. Safety and effectiveness of extended temozolomide in glioblastoma patients

    … by chemoradiation and six cycles of adjuvant temozolomide. The benefit of extending temozolomide beyond six cycles remains controversial. We investigated the effect of extended temozolomide on time to death. METHODS: A population-based retrospective cohort study was conducted using …

    queens Repository record for Safety and effectiveness of extended temozolomide in glioblastoma patients (opens in a new tab)

  4. DLL4 and JAG1 in the Glioblastoma Response to Temozolomide Chemotherapy

    … of surgery followed by radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. Prognosis is poor, with a median survival of 14.6 months following diagnosis. Treatment often fails due to intrinsic or acquired TMZ resistance of a small population of cells termed glioma cancer stem cells (GCSCs). …

    plymouth Repository record for DLL4 and JAG1 in the Glioblastoma Response to Temozolomide Chemotherapy (opens in a new tab)

  5. Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor

    … 14 patients with advanced HPC/SFT who received temozolomide and bevacizumab systemic therapy, the overall RECIST response rate was 14%, with the overall Choi response rate of 79%. The median PFS for the cohort was 9.7 months with a median 6-month progression free rate of 78.6%. The most …

    uthsc Repository record for Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor (opens in a new tab)

  6. Overcoming toxicity and resistance limitations of the anticancer drug temozolomide

    Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2026-12-01

    uiuc Repository record for Overcoming toxicity and resistance limitations of the anticancer drug temozolomide (opens in a new tab)

  7. Preventing the Emergence of Temozolomide Resistance in Glioblastoma by PARP Inhibition

    Temozolomide (TMZ) is active against the subset of glioblastomas (GBMs) in which the O6-methylguanine DNA-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, virtually all MGMT-methylated tumors acquire TMZ resistance and regrow in patients. In a preliminary study, we …

    calgary Repository record for Preventing the Emergence of Temozolomide Resistance in Glioblastoma by PARP Inhibition (opens in a new tab)

  8. Metabolomic Studies of Temozolomide Response in Patient-Derived Models of Glioblastoma

    … is an aggressive primary brain tumour for which temozolomide (TMZ) remains a core component of first-line therapy as the only systemic drug with an established survival benefit in this setting. However, over half of patients exhibit intrinsic or acquired resistance and clinical tools remain …

    mcmaster Repository record for Metabolomic Studies of Temozolomide Response in Patient-Derived Models of Glioblastoma (opens in a new tab)

  9. Single-nucleotide-resolution genomic maps of temozolomide-induced DNA adducts in glioblastoma

    Temozolomide (TMZ) is widely used for glioblastoma (GBM) therapy and functions by inducing DNA alkylation. Tumor cell killing is driven by repair pathways that eventually lead to apoptosis in fast replicating cells. While the combination of TMZ and radiother-apy improves overall survival by …

    ethz Repository record for Single-nucleotide-resolution genomic maps of temozolomide-induced DNA adducts in glioblastoma (opens in a new tab)

  10. Tetra-o-methyl nordihydroguaiaretic acid and Temozolomide work synergistically on Glioblastoma Multiforme tumors

    … poorly to the current treatment methods, temozolomide (TMZ) and radiation. Tetra-O-methyl-nordihydroguaiaretic acid (M4N), a global transcription repressor of genes, is potent when used on GBM cell lines. Here, we investigate the effects of M4N in combination with TMZ on GBM cell lines. …

    jhu Repository record for Tetra-o-methyl nordihydroguaiaretic acid and Temozolomide work synergistically on Glioblastoma Multiforme tumors (opens in a new tab)

  11. Temozolomide-Induced Mismatch Repair Deficiency Accelerates Tumor Growth and Induces Radiosensitivity in Gliomas

    … is represented by surgery, radiation therapy and temozolomide. The effectiveness of temozolomide depends on two pre-requisites. First, it requires a dysfunctional O6-methylguanine DNA methyltransferase (MGMT)-mediated DNA repair, which would otherwise directly reverse temozolomide-induced …

    zurich

  12. Subcellular proteomics of temozolomide-resistant glioblastoma multiforme cells by liquid chromatography/mass spectrometry

    … poor overall survival time of about 15 months. Temozolomide (TMZ) is the first choice of chemotherapeutic drug to treat such tumors. The main challenge remains resistance development against TMZ. Resistance causes the treatment to fail in more than 50% of the patient population. Several efforts …

    manitoba Repository record for Subcellular proteomics of temozolomide-resistant glioblastoma multiforme cells by liquid chromatography/mass spectrometry (opens in a new tab)

  13. Targeting rhabdomyosarcoma with temozolomide: how autophagy regulates TMZ-induced apoptosis in rhabdomyosarcoma cells

    … Treatment of RMS with the oral alkylating agent temozolomide (TMZ), alone or in combination with other drugs, has recently received considerable interest. However, the mechanism of action of TMZ remains unclear. The aim of this investigation was to determine if autophagy modulates TMZ-induced …

    manitoba Repository record for Targeting rhabdomyosarcoma with temozolomide: how autophagy regulates TMZ-induced apoptosis in rhabdomyosarcoma cells (opens in a new tab)

  14. Multifunctional Liposomal Carriers Encapsulating Temozolomide, RG7388 and Elacridar for Targeted Glioblastoma Multiforme Therapy

    … and efflux through the simultaneous delivery of temozolomide, RG7388 and elacridar in a single nano-carrier system. Two liposomal systems were characterized including a multilamellar system and nanoparticles in liposome system (PLL) were designed for this purpose.|The liposomes were surface …

    creighton Repository record for Multifunctional Liposomal Carriers Encapsulating Temozolomide, RG7388 and Elacridar for Targeted Glioblastoma Multiforme Therapy (opens in a new tab)

Page 1 of 15